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Abstract. Hepatocyte growth factor (HGF) is a potent 
epithelial mitogen whose actions are mediated through 
its receptor, the proto-oncogene c-Met. Two truncated 
variants of HGF known as NK1 and NK2 have been re- 
ported to be competitive inhibitors of HGF binding to 
c-Met, and to function as HGF antagonists (Lokker, 
N.A., and P.J. Godowski. 1993. J. Biol. Chem. 268: 
17145-17150;  Chan, A.M., J.S. Rubin, D.P. Bottaro, 
D.W. Hirschfield, M. Chedid, and S.A. Aaronson. 1991. 
Science (Wash. DC). 254:1382-1387).  We show here, 
however, that NK1 acts as a partial agonist in mink lung 
cells. Interestingly, NK1, which is an HGF antagonist in 
hepatocytes in normal conditions, was converted to a 
partial agonist by adding heparin to the culture me- 
dium. The interaction of NK1 and heparin was further 
studied in BaF3 cells, which express little or no cell sur- 
face heparan sulfate proteoglycans. In BaF3 cells trans- 
fected with a plasmid encoding human c-Met, heparin 
and NK1 synergized to stimulate DNA synthesis and 
cell proliferation. There was no effect of heparin on the 
IL-3 sensitivity of BaF3-hMet cells, and no effect of 
NK1 plus heparin in control BaF3 cells, indicating that 
the response was specific and mediated through c-Met. 
The naturally occurring HGF splice variant NK2 also 
stimulated DNA synthesis in mink lung cells and ex- 
erted a heparin-dependent effect on BaF3-hMet cells, 
but not on BaF3-neo cells. The activating effect of hep- 
arin was mimicked by a variety of sulfated glycosami- 
noglycans. Mechanistic studies revealed that heparin 
increased the binding of NK1 to BaF3-hMet cells, stabi- 
lized NK1, and induced dimerization of NK1. Based on 
these studies, we propose that the normal agonist activ- 
ity of NK1 and NK2 in mink lung cells is due to an acti- 
vating interaction with an endogenous glycosaminogly- 
can. Consistent with that model, a large portion of the 
NK1 binding to mink lung cells could be blocked by hep- 
arin. Moreover, a preparation of glycosaminoglycans 
from the surface of mink lung cells induced dimeriza- 
tion of NK1. These data show that the activity of NK1 
and NK2 can be modulated by heparin and other re- 
lated glycosaminoglycans to induce proliferation in 
cells expressing c-Met. 
H 
EPATOCYTE growth factor (HGF)  1 was isolated as a 
hepatocyte-specific mitogen but has subsequently 
been  found  to  stimulate  proliferation  of many 
types of epithelial cells, as well as vascular endothelial cells 
(17,  21).  Although it acts on a  broad range of epithelial 
cells, HGF has no activity on stromal cells. In fact, stromal 
cells produce HGF in many tissues containing HGF-sensi- 
tive epithelial cells, raising the possibility that HGF may 
be  important  in  local  stromal-epithelial communication 
(31, 34). In addition to its mitogenic activity, HGF stimu- 
lates  cellular  motility, which  can  be  manifested as  the 
"scattering" of cells that normally grow in tight clusters or 
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1. Abbreviations used in this paper: GAG, glycosaminoglycan; HGF, hepa- 
tocyte growth factor. 
as  enhanced  movement  across  membranes  in  Boyden 
chamber assays (8, 35, 36). HGF is also cytotoxic for some 
sarcoma cells (11)  and induces branching morphogenesis 
in certain cell types when these cells are cultured within 
collagen gels (20). 
Both the mitogenic and motogenic responses to HGF 
are mediated through its receptor c-Met, a transmembrane 
tyrosine kinase (2, 22, 23, 37).  C-Met is synthesized as a 
170-kD  precursor that is glycosylated to form a  190-kD 
species, and then proteolytically cleaved into two subunits 
(9). The larger 13 subunit contains the intracellular domain, 
with the tyrosine kinase and numerous docking sites for 
intracellular mediators, a  single membrane-spanning do- 
main, and part of the extracellular domain. The a  subunit 
is exclusively extracellular and is coupled to the [3 subunit 
by disulfide bond. 
Because c-Met is a proto-oncogene, there has been in- 
terest in the role of HGF and c-Met in cancer. Several dif- 
ferent epithelially derived tumors (4-6, 15, 24, 28, 40) and 
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protein. In addition, HGF stimulates proliferation of mam- 
mary epithelial cells (33), and high HGF levels in primary 
breast  cancers have  been  associated  with  faster  relapse 
and shortened survival time (38). 
Full-length  HGF  is  a  90-kD  protein  composed of an 
NH2-terminal domain, four consecutive kringle domains, 
and  a  carboxy-terminal protease-like  domain,  and  two 
truncated variants of HGF have been described as com- 
petitive  HGF  antagonists.  The  first  variant,  designated 
NK2 because it consists of the HGF NH2-terminus through 
kringle 2, is the naturally occurring product of an alterna- 
tively spliced HGF mRNA  (3).  NK2 failed to stimulate 
proliferation in  B5/589 mammary  epithelial  cells,  but  it 
bound  to c-Met  and  blocked the mitogenic response to 
full-length HGF (3). Hartmann et al. confirmed that NK2 
lacks mitogenic activity but found that it retained the abil- 
ity to induce scattering in MDCK cells (10). These investi- 
gators suggested that the interaction of NK2 with c-Met is 
sufficient to  activate the  intracellular signaling  required 
for motility but that full-length HGF is required to acti- 
vate those signals involved in mitogenesis. NK2 was dis- 
covered in medium conditioned by SK-LMS-1 cells, but 
the same alternatively spliced transcript has been identi- 
fied in normal human placenta, suggesting that NK2 has a 
physiological function (18). 
More  recently, Lokker and  Godowski  showed  that  a 
shorter HGF variant, truncated after the first kringle do- 
main  (amino  acids  32-210)  and  designated  NK1,  also 
blocks binding of HGF to c-Met and is a potent inhibitor 
of HGF-induced DNA synthesis in rat hepatocytes (16). 
However, they also found that high concentrations of NK1 
induced a small but detectable increase in tyrosine phos- 
phorylation of c-Met in A549 cells, consistent with a weak 
agonist activity. 
We have studied NK1 further to assess its potential as 
an anticancer agent, and we report here that the nature of 
the  response  to  NK1  varies  in  different cell types.  We 
show that NK1 is an HGF antagonist in hepatocytes, as de- 
scribed previously (16), but that in mink lung cells, NK1 
has a direct stimulatory effect on DNA synthesis. To un- 
derstand the discrepancy between hepatocytes and mink 
lung cells, we examined the effects of heparin on NK1 ac- 
tivity because NK1, like full-length HGF, binds heparin 
(16), and heparin promotes dimerization of HGF and aug- 
ments the response to low doses of HGF in hepatocytes 
(41). In addition, heparan sulfate proteoglycans are impor- 
tant  for the  activity of FGF  and  other heparin  binding 
growth factors (13, 32). We show here that there is a syner- 
gistic interaction of heparin with NK1 to stimulate DNA 
synthesis in cells expressing c-Met. Similar results were ob- 
tained with the naturally occurring variant NK2. Data such 
as these lead us to propose that glycosaminoglycans on the 
cell surface can interact with NK1  and NK2 to promote 
proliferative activity through c-Met, turning these variants 
from antagonists to agonists. 
Materials and Methods 
Materials 
Recombinant human HGF was produced from medium conditioned by a 
mammalian cell line derived by stable transfection with a full-length HGF 
eDNA, as previously described (41).  NK1 was produced in  Escherichia 
coli and purified as described by Lokker et al. (16). NK2 was produced by 
transient transfection in 293 cells with a eDNA corresponding to the se- 
quence of human NK2 described by Chan et aL (3). Conditioned medium 
was passed over S-Sepharose and washed with 0.25 M NaC1, 20 mM Tris, 
pH 7.5, and NK2 was eluted by a NaCI gradient from 0.25 to 1.5 M  into 
tubes containing 1 mg/ml BSA as carrier. Fractions that contained NK2 
were identified by ELISA (see below) and pooled. 
IL-3 was obtained from Genzyme Corp. (Boston, MA). Heparin, de- 
N-sulfated heparin, dextran, dextran sulfate, pentosan polysulfate, hepa- 
ran sulfate, chondroitin sulfate, and sodium sulfate were purchased from 
Sigma Chemical Co. (St. Louis, MO). Phycoerythrin-streptavidin was pur- 
chased  from Jackson  ImmunoResearch Laboratories  (Avondale,  PA). 
Bis(sulfosuccinimidyl) suberate (BS  3) was purchased from Pierce Chemi- 
cal Co. (Rockford, IL). 
NK1/NK2 ELISA 
A  sandwich ELISA for NK1 was developed using two Abs against NK1 
(kindly provided by Dr, Jin Kim and Kelly Tabor, Genentech Inc., South 
San Francisco, CA). Microtiter plates were coated overnight at 4°C with 
2 p~g/ml antibody 8A8 in sodium carbonate buffer, pH 9.6. The plate was 
then blocked with PBS, 0.5%  BSA, 0.01% thimerosal (150  Ixl) for 2 h. 
This and all subsequent steps were performed at room temperature on an 
orbital shaker. The blocking buffer was discarded, the plate was washed 
three times with PBS, 0.05% Tween-20, 0.01% thimerosal, and the sample 
was incubated for 2 h. The plate was again washed three times and incu- 
bated for 2  h  with biotinylated anti-NK1 antibody 6D5. The plate was 
then washed three times, incubated with HRP-streptavidin (Zymed Labo- 
ratories, Inc., South San Francisco, CA) for 30 min, and washed three 
more times. O-phenylene diamine and H202 were added, and color was 
allowed to develop for 10-20 min. The reaction was stopped with sulfuric 
acid and absorbance at 492 nm, less the absorbance at the reference wave- 
length of 405 nm, using an microtiter plate reader. This assay recognizes 
NK1 and NK2. 
Hepatocytes and Mink Lung Cells 
Hepatocytes were isolated from adult female Sprague-Dawley rats by col- 
lagenase perfusion, according to the methods of Garrison and Haynes (7). 
The  cells were  washed three  times with  William's E  medium supple- 
mented with 10 p.g/ml transferrin, 1 p,g/ml insulin, 1 mg/ml BSA, 50 p,g/ml 
Gentamycin, 2 mM glutamine, 100 IU/ml penicillin, and 100 t~g/ml strep- 
tomycin, resuspended in the same medium, and then seeded into a 96-well 
plate (5,000 cell per well) with the factors to be tested. 16 h later, 1 IxCi 
[3H]tbymidine was added,  and  after an additional 24 h, the cells were 
transferred onto plates with a  cell harvester (Unifilter GF/B, Filtermate 
196; Packard Instrument Co., Inc., Downers Grove, IL). The amount of 
radioactivity incorporated into DNA was measured in a microplate scintil- 
lation counter (Top Count; Packard Instrument Co., Inc.). 
Mink lung cells were passaged in MEM, 10% FBS, 2 mM glutamine, 
100 U/ml penicillin, and 100  ~g/ml streptomycin. To measure DNA syn- 
thesis, the cells were released from the flask with trypsin-EDTA, washed 
twice with serum-free assay medium (DME/F12 (50:50),  2 mM glutamine, 
and 1 mg/ml BSA), and seeded into 96-well plates (10,000  cells per well) 
containing the factors to be tested. DNA synthesis was then measured as 
described above for hepatocytes. 
BaF3-hMet Cells 
A full-length cDNA for human c-Met was inserted into the pRK5-tk.neo 
vector. The resulting plasmid was linearized  and introduced into BaF3 
cells by electroporation at 250 V, 800 t~F. Controls were transfected with 
the empty vector. Transformants were selected in 2 mg/ml G418, cloned 
by limiting dilution, and the resulting cell lines were tested for their ability 
to respond to HGF, as described below. Those cell lines that responded to 
HGF were  also found to express c-Met by Western blotting (data  not 
shown). 
Parental BaF3  and the transfected sublines were passaged in RPMI 
1640 supplemented with 10% FBS, 2 mM glutamine, I~-mercaptoethanol 
(4 IxUL), and 5% WEHI-conditioned medium as a source of IL-3. Trans- 
fected sublines were maintained in 1 mg/ml G418. To measure DNA syn- 
thesis, the cells were washed twice with RPMI 1640 containing 10% FBS 
and glutamine, but no IL-3, and resuspended in the same medium; then 
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be tested.  The following morning, 1  ~,Ci [3H]thymidine  was added,  and 
the amount incorporated into DNA was measured 7 h later. To measure 
cell growth, cells were seeded in a 24-well plate in 1 ml of the above me- 
dium containing the factors to be tested, but no IL-3, and 7 d later, cells 
were counted using a particle counter (ZM; Coulter Corp., Hialeah, FL). 
Binding Analysis 
BaF3-hMet cells were washed, resuspended in cold Dulbecco's PBS, 0.5% 
BSA, and then incubated with increasing concentrations of NK1 (0.1-20 nM) 
in the absence and presence of 1 tLg/ml heparin for 1 h at 4°C. The cells 
were then washed twice and resuspended in buffer containing 2 i~g/ml bi- 
otinylated mAb 6D5.  After a  30-min  incubation, the cells  were washed 
and resuspended in 50 ixl phycoerythrin-streptavidin (final dilution 1:50). 
After an additional 30 min on ice, the cells were washed and resuspended 
in buffer. Fluorescence was quantitated by flow cytometry, using an EPICS 
Elite instrument (Coulter Corp.) equipped with an argon ion laser.  Or- 
ange fluorescence at 575  +__  15  nm was collected  after 488-nm laser (15 
mW) excitation.  10,000 cells were analyzed,  and the mean fluorescent in- 
tensity was calculated.  Background fluorescence in the absence of NK1 
was subtracted. 
Dimerization 
The cross-linking reagent bis(sulfosuccinimidyl) suberate was added  (1 
mM final concentration) to a tube containing 1 p~g NK1 with or without 1 ~g 
heparin in a total volume of 20 pJ of 0.15 M NaCI. After 20 min, the reac- 
tion was quenched by addition of 5  pJ of 1 M  Tris-HCl, pH 6.8. SDS- 
PAGE  sample buffer with 10  mM  J3-mercaptoethanol  was added,  and 
then the samples were heated at 100°C for 7 min and loaded onto a 4-20% 
SDS gel. After electrophoresis, bands containing NK1 were identified  by 
Western blotting with a  cocktail  of anti-NK1  mAbs, followed by HRP- 
sheep anti-mouse IgG (Amersham Corp., Arlington Heights, IL) and de- 
tection with the SuperSignal CL kit (Pierce Chemical Co.). 
Dimerization was confirmed by testing the cross-linked products in a 
dimer-specific NK1 ELISA. The assay was performed as described above, 
except that the plate was coated with antibody 6D5 rather than 8A8.  In 
this format, the same antibody is used both for capture and detection. Mo- 
nomeric NK1  is  not detected  because binding to the capture antibody 
blocks the epitope from the detection antibody, but dimeric NK1 presents 
two epitopes, allowing a signal to be generated. Samples to be tested were 
cross-linked as described above, and then diluted to 1 ml with 0.5 M NaCI 
to minimize nonspecific aggregation. 
Preparation of  Mink Lung Cell 
Surface Glycosaminoglycans 
To release cell surface glycosaminoglycans  (GAGs), six confluent 150-mm 
plates of mink lung cells were rinsed with PBS  and incubated with 2 ml 
trypsin-EDTA at 37°C until the cells detached. The trypsin solution was 
then collected,  pooled,  and  after  removing the  cells  by centrifugation, 
heated  in  a boiling water bath for 30 min to denature the trypsin. The 
GAGs were then partially purified by anion exchange chromatography on 
a 1-ml column of DEAE-Sephacel. After washing with 5-column volumes 
of 1% NaCI, bound material was eluted with 16% NaC1, dialyzed  against 
water, and concentrated by vacuum centrifugation. 
Results 
NK1 in Hepatocytes and Mink Lung Cells 
We found that although NK1 blocked the effects of HGF 
in  hepatocytes, it was only a  weak inhibitor  of HGF in 
mink lung cells and had activity of its own in the absence 
of HGF (Fig. 1). This type of behavior is characteristic of a 
partial agonist, which weakly activates the receptor but oc- 
cupies the binding site, blunting responses to a full agonist. 
The antagonistic activity of NK1  can be explained by its 
ability to competitively inhibit HGF binding to c-Met (16), 
but to have agonist and antagonist activity in different cell 
lines was surprising. Because (a) NK1 binds heparin (16); 
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Figure 1.  NK1 is antagonist  in hepatocytes but partial agonist in 
mink lung cells. Hepatoctyes (A) or mink lung cells (B) were cul- 
tured overnight with the indicated  concentrations  of NK1 alone 
or NK1 with a maximally effective concentration of HGF (30 ng/ml 
for hepatocytes, 10 ng/ml for mink lung cells). [3H]thymidine was 
added,  and 24 h later the amount incorporated into DNA was 
measured. Shown are the mean _+ SEM of six replicates  from a 
representative experiment. 
(b)  heparin  can  augment  the  activity  of HGF  (41)  and 
other heparin-binding  growth factors (1, 26,  39);  and (c) 
heparin-like molecules on the cell surface are important 
for FGF activity (13, 32), we hypothesized that the agonist 
activity of NK1 in mink lung cells might be due to local ac- 
tivation of NK1 by proteoglycans on the surface of mink 
lung cells. Consistent with that hypothesis, Table I shows 
that mink lung cells have a large capacity to bind NK1 and 
that most of the NKI binding is displaced by heparin, sug- 
gesting it is to a heparin-like molecule. 
Heparin Converts NK1 from Antagonist to Partial 
Agonist in Hepatocytes 
One prediction from our hypothesis is that NK1 would be- 
come an agonist in the presence of the  appropriate gly- 
cosaminoglycan. This was tested in hepatocytes, using hep- 
arin as the glycosaminoglycan. As shown in Fig. 2 A, there 
were two changes when heparin was added to the culture 
medium. First, the response to this dose of HGF (10 ng/ 
ml) increased, which is consistent with our earlier report 
(41). Second, the response to NK1 switched from antagonist 
to partial agonist and resembled qualitatively the response 
Table L Heparin Displaces NK1 Binding to Mink Lung Cells 
Specific  Inhibition 
NK1  Heparin  binding  by heparin 
Fluorescence 
ng/ml  Ixg/ml  units  % 
0  0  0.0 
100  0  18.7 
100  1  0.4  97.9 
1,000  0  130.2 
1,000  1  6.4  95.1 
Mink lung cells were incubated with the indicated concentrations of NKI in the ab- 
sence and presence of 1 p.g/ml  heparin for 1 h at 4°C. The ceils were then washed 
twice with PBS, and the amount of NK1 bound was detected by adding an mAb to 
NK1 followed  by phycoerythrin-streptavidin  and quantitation by flow cytometry. Spe- 
cific binding was calculated by subtracting  the amount of fluorescence detected in the 
absence of NK  1 (4.8 fluorescence  units). Data are the mean of duplicates that varied <5%. 
Schwall et al. Heparin Promotes Agonist Activity of NK1 and NK2  711 A, NKl+Heoarin in Heoatocvtes 
25,000 
(:NK,  A,one 
20~00  NKt+HGF 
'o 
"r 
,"  5,~C" 
0 
o--_o-.-o.---o 
,  ,  ,  ,  ,  ,  ,  , 
o  lO  10o  1,ooo  0  lO  1oo  1,0oo 
NK1 (ng/ml) 
B. Heloarirl-Dose Response 
2s,o00 - 
Control 
•  NK1,100 ng/ml 
.¢~  20,000-  ~  NK1, ~lag/ml 
E  Q. 
15000 -  v 
"r  5,~  - 
0  ,  ,  ,  ,  I 
0  0.1  1  10  100 
Heparin (gg/ml) 
Figure 2.  Heparin converts NK1 to agonist in hepatocytes. (A) 
Hepatocytes were cultured overnight in the presence of the indi- 
cated concentrations of NK1 alone or with 10 ng/ml HGF in ei- 
ther control medium (left) or medium containing 1 p,g/ml heparin 
(right). [3H]thymidine  was added, and 24 h later the amount in- 
corporated into DNA was measured. (B) Hepatocytes were cul- 
tured  for 24 h  with  0.1  (closed circles) or  1  txg/ml (half-filled 
squares)  NK1  plus  the  indicated  concentrations  of  heparin. 
[3H]thymidine  was added, and 24 h  later the amount incorpo- 
rated into DNA was measured. Data shown in A  and B are the 
mean -  SEM of six replicates from a representative experiment. 
to NK1  in  mink  lung  cells  (see  Fig.  1  B).  The  heparin 
dose-response  curve  was  bell-shaped,  with  maximal  re- 
sponses at ~10 ixg/ml heparin (Fig. 2 B). 
NK1  + Heparin Has Agonist Activity in BaF3 
Cells Expressing c-Met 
The synergy between NK1 and heparin was further inves- 
tigated in BaF3 cells, which are reported to lack cell sur- 
face heparan sulfate proteoglycans (25). These cells do not 
normally express c-Met and are insensitive to HGF, but, as 
illustrated  in Fig. 3 A, HGF was able  to stimulate  DNA 
synthesis in BaF3-hMet cells, which were derived by trans- 
fection  with  a  cDNA  for  full-length  human  c-Met.  Re- 
sponses to HGF were observed in both the  absence  and 
presence of heparin, but heparin increased the sensitivity to 
HGF ~10-fold, with no effect on the magnitude of the maxi- 
mal response. We recently reported a similar sensitizing ef- 
fect of heparin on HGF responses in rat hepatocytes (41). 
As  in  hepatocytes,  NK1  stimulated  DNA  synthesis  in 
BaF3-hMet  cells  when  heparin  was  included  in  the  me- 
dium (Fig. 3 B). The difference in potency between NK1 
and HGF is consistent with the lower affinity of NK1 for 
c-Met (16).  The effects of heparin  on HGF and NK1 re- 
sponsiveness were specific, as heparin had no effect on the 
response to IL-3 (Fig. 3 C). Moreover, there was no effect 
of HGF or NK1 with or without heparin in control BaF3- 
neo cells that had been transfected with an empty vector 
(Fig. 4). These data indicate that the response to NK1  + 
heparin is specific and is mediated through c-Met. 
Consistent with the data in hepatocytes, the heparin dose- 
response curve in BaF3-hMet cells was again bell-shaped 
(Fig. 5).  Maximal responses  occurred at  1-10  p~g/ml hep- 
arin with 1 ixg/ml NK1. A  small response to NK1 at 1 ixg/ml 
was sometimes observed in the absence of heparin, so we 
extended  the  NK1  dose-response  curve.  A  modest  re- 
sponse to NK1 was noted at 10 I~g/ml in the absence of hep- 
arin,  which then  returned  to baseline  at  100  ixg/ml NK1 
(data not shown). However, in the presence of heparin, re- 
sponses occurred at NK1 doses as low as 100 ng/ml, which 
had no effect in the absence of heparin (Fig. 5). A  small ef- 
fect of heparin alone was also sometimes observed, espe- 
cially at 10 ixg/ml (see Fig. 5). The reason is unclear, but at 
1 t~g/ml,  which was the dose used in most studies, this ef- 
fect  was  inconsistent  and  nonspecific in  that  it  also  oc- 
curred in BaF3-neo cells (see Fig. 4). In contrast, the effect 
of NK1  +  heparin  was  always much  larger,  was  consis- 
tently observed in every experiment, and was only seen in 
cells expressing c-Met. 
DNA synthesis is necessary but not sufficient for cellu- 
lar proliferation.  To determine  whether  NK1  +  heparin 
could stimulate  progression through the entire cell cycle, 
growth was measured by counting cells after 7 d. As shown 
in Table  II, NK1 alone had very little  effect, but NK1  + 
heparin  increased  the  number  of cells  by  ~17-fold.  For 
comparison,  10  ng/ml  HGF  in  the  absence  of  heparin 
(~ED50;  see Fig. 3)  caused a  sevenfold increase,  and  in 
the  presence  of  heparin  (~ED90),  a  24-fold  increase. 
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Figure 3.  Heparin  alters  re- 
sponse of BaF3-hMet cells to 
HGF and NK1 but not to IL-3. 
BaF3-hMet  cells  were  cul- 
tured 16 h with the indicated 
concentrations of HGF (A), 
NK1 (B), or IL-3 (C) in the 
absence  (open  circles)  or 
presence (closed circles) of 1 
txg/ml  heparin.  [3H]thymi- 
dine was added, and 7 h later 
the  amount  incorporated 
into  DNA  was  measured. 
Data shown are the mean  -+ 
SEM of four replicates from 
a representative experiment. 
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not in BaF3-neo cells. BaF3-hMet cells (A), which were derived 
by transfection with a eDNA for full-length human c-Met, and 
BaF3-neo cells (B), transfected with the empty nee vector, were 
cultured for 16 h with 1 i~g/ml NK1 or 10 ng/ml HGF in the ab- 
sence (hatched bars) or presence (gray bars) of 1 i~g/ml heparin. 
[3H]thymidine was added, and 7 h later the amount incorporated 
into DNA was measured.  Bars represent  the mean  _+  SEM of 
four replicates from a representative experiment. 
Thus, NK1 +  heparin is a true mitogen in these cells, capa- 
ble of eliciting proliferative responses comparable to those 
to full-length HGF. 
Heparin Specificity 
To determine the specificity of the activating effect of hep- 
arin, a variety of sulfated and nonsulfated polysaccharides 
was tested.  As shown in Table  III, heparin,  dextran sul- 
fate, pentosan polysulfate, and chondroitin sulfate syner- 
gized with NK1, but de-N-sulfated heparin, dextran, and 
sodium sulfate  had no effect. Heparan sulfate  enhanced 
the response to full-length HGF but had no effect on NK1 
activity, even at concentrations 100-fold greater than hep- 
arin. These data suggest that NK1 and HGF have different 
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Figure 5.  Heparin  dose-response  with NK1 in BaF3-hMet cells. 
BaF3-hMet cells were cultured for 16 h with 0.1 (closed  circles) or 
1 ~g/ml (half-filled squares) NK1 in the absence or presence of 
the  indicated  concentrations  of  heparin.  [3H]thymidine  was 
added,  and  7 h later  the  amount  incorporated  into  DNA was 
measured. Shown are the mean -+ SEM of four replicates from a 
representative experiment. 
Table II. NK1 + Heparin Stimulates Growth of  BaF3-hMet 
Cells 
Addition  Cells per ml 
Control  11,400 _+ 2,900 
NKI  (1  p.g/ml)  21,340 _+ 3,000 
NK1  +  heparin (1  p.g/ml)  177,900  _+  10,270 
HGF (10 ng/ml)  76,700 _+ 5,400 
HGF +  heparin (1 p~g/ml)  248,300  +  22,100 
BaF3-hMet cells were seeded at a density of 26,000 cells per ml in medium containing 
1 Izg/ml NK1 or 10 ng/ml HGF in the absence or presence of I izg/ml heparin. After 7 d, 
the number of cells was counted.  Data are the mean -+ SEM of four replicates from a 
representative experiment. 
structural requirements for their interactions with sulfated 
polysaccharides. 
Heparin Enhances NK1 Binding to BaF3-hMet Cells 
A  series  of experiments  was conducted to better  under- 
stand the mechanism for the heparin-induced activation of 
NK1. One possibility is that heparin acts on the cells to in- 
duce responsiveness to NK1. However, BaF3-hMet cells 
that had been preincubated overnight with heparin did not 
respond when  subsequently challenged with NK1  in the 
absence of heparin (data not shown). Thus, there is a re- 
quirement for both agents to be present simultaneously. 
To  determine  whether  heparin  increased  the  cellular 
binding of NK1, BaF3-hMet cells were incubated with in- 
creasing concentrations of NK1, with and without heparin, 
and bound NK1 was detected with an excess of biotiny- 
lated anti-NK1 mAb, followed by phycoerythrin-streptavi- 
din and fluorescence quantitation by flow cytometry. This 
approach avoids labeling-induced chemical alterations  in 
the ligand, and although absolute amounts of NK1 bound 
cannot be  determined,  it  is  possible  to measure  affinity 
and to make relative comparisons of receptor number. Us- 
ing this method, specific binding of NK1 was detected in 
BaF3-hMet cells, and the amount of binding was increased 
in the presence of heparin, whereas no binding of NK1 was 
detected in BaF3-neo cells in either presence or absence of 
heparin (Fig. 6 A). The binding of NK1 to BaF3-hMet cells 
was further characterized by performing Scatchard analysis 
of saturation binding curves. As shown in Fig. 6 B, heparin 
caused the apparent affinity of NK1 to increase ,--40-fold, 
and  the  apparent  number  of receptors  increased  nearly 
twofold. 
Heparin Promotes Stabilization and Dimerization 
of NK1 
In the absence of heparin, NK1 did not antagonize HGF 
activity in BaF3-hMet cells (data not shown) at the same 
concentrations that inhibit binding of HGF to c-Met in cell- 
free systems (16) and blocked HGF activity in hepatocytes 
(Fig.  1). This was true whether the BaF3-hMet cells were 
tested in BaF3 medium or in hepatocyte medium (data not 
shown).  To  determine  whether  NK1  was  being  inacti- 
vated, NK1 was preincubated overnight at 37°C in BaF3 
culture medium with or without heparin. Heparin was then 
added to samples that had been preincubated in the ab- 
sence of heparin, and the ability of the preincubated sam- 
ples to stimulate DNA synthesis in BaF3-hMet cells was 
Schwall et al. Heparin Promotes Agonist Activity of NK1 and NK2  713 Table IlL Effect of Sulfated and Nonsulfated Polysaccharides  on the Activity of NK1, HGF, and NK2 in BaF3-hmet Cells 
[3H]thymidine  incorporation  [3H]thymidine  incorporation 
CoFactor  Concentration  Control  NKI (1 p.g/ml)  HGF (10 ng/ml)  Control  NK2 (100 ng/ml) 
tzg/ml  cpm per well  cpm per well 
Control  -  2,135 ±  40  4,216 ---  174  11,035  +-  170  3,831  ±  523  4,153 ±  450 
Heparin  10  3,323 +- 67  12,558  ±  145  15,482 ±  358  6,016 ±  260  9,674 ±  514 
DE-N-Sulfate Heparin  10  2,196 ±  70  4,404 ±  175  11,030 ±  374  4,059 --- 227  4,233 ±  353 
Dextran sulfate  10  3,638 ±  60  11,013  ±  340  17,119  ±  335  6,101  ±  89  11,583  ±  1,015 
Dextran  10  2,254 ±  108  4,264 ±  410  11,154  ±  516  4,653 ±  237  5,780 --- 282 
Sodium sulfate  10  2,374 _  93  4,690 ±  65  11,043  ±  467  6,049 ±  484  5,204 ±  227 
Pant•san polysulfate  10  2,858 +- 43  8,909 ±  481  15,788  ±  731  5,456 +  171  12,754 ±  564 
Heparin sulfate  10  2,021  ±  72  5,330 ±  197  13,989 +- 559  4,131  ±  195  7,266 ±  648 
Control  -  2,243 ±  38  2,762 ±  268  11,003  ±  459  3,272 ±  64  3,098 ±  71 
Heparan  1  2,547 ±  116  6,668 ±  366  18,640 --- 393  3,262 ±  133  6,916 ±  202 
Heparan sulfate  1  2,083 +  110  2,446 ±  75  16,718  ±  595  ND  ND 
10  1,912  _+  133  2,641  ±  77  16,732 _  750  2,554 ±  94  4,602 ±  210 
100  1,996  ±  132  3,197 ±  116  13,538  _  1,021  ND  ND 
Control  -  2,918 ±  142  2,792 ±  202  ND  2,918 ±  142  2,472 ±  90 
Heparin  1  2,112 ±  119  6,758 ±  212  ND  2,112 ±  119  6,247 ±  178 
Chrondroitin sulfate  100  2,460 ±  99  5,039 ±  230  ND  2,460 ±  99  5,042 -  47 
BaF3-hmet cells were cultured for 16 h with NKI, HGF, or NK2 in combination with a variety of sulfated and nonsulfated polysaccharides.  [3H]thymidine  was added and the 
amount incorporated into DNA was measured 7 h later. Values shown are the mean + SEM of four replicates from a representative experiment. 
A. NK1  Binding to BaF3-hMet vs BeF3-neo Cells 
NK1 Bound 
(Fluorescence Units) 
Addition  BaF3-hMet  BaF3-neg 
None  0.00  0.00 
Heparin  0,01  0.00 
NK1  1.02  0.02 
NKl+Heparin  2.67  0.03 
B. Scatchard  Analysis 
kD  B  ma_..  x 1 
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Figure 6.  Heparin enhances binding of NK1 to BaF3-hMet cells. 
(A) BaF3-hMet cells and BaF3-neo cells were incubated for 1 h at 
4°C with 10 nM NK1 in the absence or presence of 1 I~g/ml  hep- 
arin. Unbound NK1 was washed away, and bound NK1 was de- 
tected with biotinylated anti-NK1 mAb 6D5 followed by phyco- 
erythrin-streptavidin and quantitation  by flow cytometry. 10,000 
cells were analyzed, and the mean fluorescent intensity  was calcu- 
lated. Nonspecific fluorescence in the absence of NK1  has been 
subtracted. Shown are the means of duplicates that did not differ 
by  >8%.  (B)  Scatchard  analysis was  performed  on  saturation 
binding data for NK1 binding to BaF3-hMet cells in the absence 
(open squares)  and presence (closed circles)  of 1  ~g/ml heparin. 
Each point is the mean of duplicates that varied <10%. 
measured, compared to freshly prepared NK1 or NK1  + 
heparin. As shown in Table IV, NK1 that had been prein- 
cubated overnight in medium without heparin was com- 
pletely inactive,  even though heparin  was present  when 
the  cells  were  challenged  with  the  sample.  In  contrast, 
NK1  that was preincubated  with  heparin  retained  some 
activity. 
Receptor dimerization is an important process in growth 
factor receptor activation, and the bell shape of the hep- 
arin dose-response curve is consistent with a dimerization 
mechanism. For these reasons, we examined the ability of 
heparin  to  induce  dimerization  of NK1.  A  bifunctional 
cross-linker was added to solutions of NK1 alone or NK1 
with heparin. The samples were then separated by SDS- 
PAGE,  and  bands  containing  NK1  were  identified  by 
Western blotting. The results  are shown in Fig.  7.  In the 
absence of heparin, a single band with apparent molecular 
weight of ~26,000 was detected. In the presence of hep- 
arin, there was an additional band at ~53,000, consistent 
with an NK1 dimer, along with smaller amounts of a larger 
species  consistent  with  a  trimer.  The  larger  molecular 
Table IV. Heparin Stabilizes NK1 in BaF3 Medium 
Addition  [3H]thymidine  incorporation 
cpm per well 
Control  4,566 +  84 
NK1  4,867 ±  156 
Heparin  5,222 ±  176 
NK1  +  heparin  12,312  ±  139 
NK1 preincubated without heparin  5,285 ±  201 
NK1 preincubated with heparin  7,862 ±  84 
NK1 (100 ng/ml) was preincubated with or without 1 p.g/ml heparin in BaF3 culture 
medium for 16 h at 37°C, 5% CO  2. The next morning BaF3-hMet cells were added. At 
this time, heparin was also added to the NK1 that was preincubated without heparin so 
that heparin would be present during the challenge incubation. For comparison, cells 
were also added to wells containing freshly prepared NKI  and heparin. The next 
morning [3H]thymidine  was added, and the amount incorporated into DNA was mea- 
sured 7 h later. Shown are the mean -+ SEM of four replicates from a representative 
experiment. 
The Journal of Cell Biology, Volume 133, 1996  714 Figure 7.  Dimerization of NK1. (A) The bifunctional  cross-linker BS  3 was added to tubes containing NK1 alone or NK1 with heparin, 
dextran sulfate, or dextran. The samples were then analyzed by Western blotting with anti-NK1 antibodies. Molecular weight markers are 
shown on the side. (B) Samples of NK1 with increasing concentrations of heparin were analyzed as described  above. (C) NK1 was incu- 
bated with a crude preparation of glycosaminoglycans from mink lung cells (see Materials  and Methods)  and analyzed as described for 
A. The numbers under the lanes in B and C are OD readings from the dimeric NK1 and total NK1 ELISAs. 
weight  bands  were  also  observed  with  dextran  sulfate, 
which activates NKll but not with dextran, which does not 
activate NK1 (see Table III). The higher molecular weight 
bands were not detected when the cross-linker was omit- 
ted (data not shown). 
To confirm that the higher molecular weight bands were 
oligomers, we adapted the NK1 ELISA to detect dimeric 
and multimeric, but not monomeric, NK1. By using a sin- 
gle anti-NK1 mAb for both capture and detection, mono- 
meric NK1 is not detected because binding of the epitope 
by the capture antibody prevents its binding to the detec- 
tion  antibody.  Dimeric NK1, however, presents  an addi- 
tional epitope for the detection antibody. In the dimer for- 
mat, a  signal was detected for NK1 with heparin but not 
for either reagent alone (Table V). In the normal format, 
OD was detected for NK1 alone and for NK1 plus heparin, 
indicating  that  NK1  was  present  in  both  samples.  The 
greater OD for NK1 plus heparin vs NK1 alone in the nor- 
mal format is also consistent with dimerization/multimer- 
ization,  as additional  epitopes for the  detection antibody 
would be present on each captured molecule. 
The heparin dose-response curves for NK1 activation in 
both  hepatocytes  and  BaF3-hMet  cells were bell-shaped 
(see Figs. 2 B  and 5); i.e., the response diminished at high 
concentrations of heparin. As shown in Fig. 7 B, dimeriza- 
tion of NK1 was also diminished as the concentration  of 
heparin  was  increased.  Interestingly,  a  preparation  of 
GAGs from the surface of mink lung cells was also able to 
induce dimerization of NK1 (Fig. 7 C). A  faint band in the 
Table V. Heparin Induces NK1 Dimerization 
NK1 ELISA (OD 492-405) 
Sample  Dimer format  Normal format 
Control  0.004 _+ 0.000  0.004 _  0.001 
NKI  0.007 _+ 0.000  0.875 _+ 0.018 
Heparin  0.006 -+ 0.000  0.003  _+ 0.000 
NKI  +  heparin  0.323 _+ 0.025  2.620 -_+ 0.012 
NK1 that had been incubated  in the presence  or absence of heparin  was cross-linked 
with BS 3 and then assayed in the normal NK1 ELISA, which recognizes  monomeric 
and dimeric NK1  (right column) or an adaptation  of the ELISA designed  to detect 
only dimeric NK1 (left column). Shown are OD values after development  of the HRP. 
Data are the mean -+ SEM of four replicates. 
dimer position was sometimes observed for NK1 samples 
without heparin, suggesting that NK1 may have a natural 
but weak tendency to dimerize. 
Heparin Promotes Agonist Activity of  Naturally 
Occurring Variant NK2 
All of the experiments shown above were conducted with 
NK1, but similar results have also been obtained with the 
naturally occurring variant NK2, which also binds heparin. 
As shown in Fig. 8 A, NK2 had activity in mink lung cells, 
and the response was similar to that induced by NK1 and 
by HGF. Fig.  8 A  also shows that the  response of mink 
lung cells to NK1, NK2, and HGF is not affected by hep- 
arin. In contrast, in BaF3-hMet cells NK2, like NK1, had 
no activity in the absence of heparin but stimulated DNA 
synthesis when heparin was present (Fig. 8 B).  Although 
the absolute magnitude of the response to NK2 +  heparin 
was only approximately twofold in this particular experi- 
ment, it was similar to that induced by NK1 +  heparin and 
by HGF. Importantly, there was no stimulatory effect of 
NK2  +  heparin in  BaF3-neo  cells  (Fig.  8  C),  indicating 
that the effect of NK2 +  heparin is specific and, like the ef- 
fect ofNK1 + heparin and HGF, is mediated through c-Met. 
As  with  NK1,  the  effect of heparin  on  NK2  activity in 
BaF3-hMet  cells was mimicked by dextran  sulfate,  pen- 
tosan polysulfate, and chondroitin sulfate, but not by de- 
N-sulfated heparin, dextran, or sodium sulfate (Table III). 
Interestingly, heparan sulfate activated NK2, although it 
had no effect on NK1. 
Discussion 
We show here that the truncated HGF variant NK1, which 
is an HGF antagonist in hepatocytes, acts as a partial ago- 
nist in mink lung cells, and interestingly, that heparin can 
convert  NK1  from  an  antagonist  to  a  partial  agonist  in 
hepatocytes. Heparin also conferred agonist activity onto 
NK1 in c-Met transfected BaF3 cells, which do not express 
the proteoglycan core protein syndecan and do not have 
endogenous cell surface proteoglycans (25).  That the re- 
sponse in BaF3-hMet cells was specific was supported by 
the findings that heparin had no effect on IL-3 sensitivity in 
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BaF3-hMet  cells. Mink lung cells (A), BaF3-hMet  cells (B), and 
BaF3-neo cells (C) were cultured  with the indicated  concentra- 
tions  of NK2,  in the  absence  or presence of 1  ixg/ml heparin. 
[3H]thymidine incorporation into DNA was measured. As posi- 
tive controls,  100 ng/ml NK1 and 10 ng/ml HGF were also in- 
cluded.  Bars in each panel represent the mean  -+ SEM  of four 
replicates from a representative experiment. 
these cells and that NK1 +  heparin had no effect on BaF3- 
neo cells. The latter observation also indicates that the ef- 
fects of NK1 +  heparin is mediated through c-Met, the same 
receptor that mediates responses to full-length HGF. 
The concentrations  over which NK1 was an agonist in 
mink lung cells and over which NK1 +  heparin was an ag- 
onist in hepatocytes and BaF3-hMet cells were high com- 
pared to those of HGF. This is due in part to the lower af- 
finity  of NK1  for  c-Met  (16),  combined  with  the  lower 
efficiency for activating c-Met, as reflected in partial ago- 
nism. Nonetheless, the concentrations of NK1 in which we 
observed agonist activity in our studies are similar to those 
in which we (Figs. 1 and 2) and others (16) have observed 
antagonistic activity in hepatocytes. 
Mechanistic studies revealed that heparin enhanced the 
binding  of BaF3-hMet  cells,  and  Scatchard  analysis  re- 
vealed that both the apparent affinity and receptor num- 
ber were increased. Since there was no binding of NK1 to 
BaF3-neo cells, the  binding to BaF3-hMet  cells must in- 
volve c-Met. The heparin-induced increase in apparent re- 
ceptor number is unlikely due to an effect on the cells be- 
cause binding was performed at 4°C; rather, it may be due 
to dimerization  of the  ligand, which would be consistent 
with the twofold magnitude of the increase. The effect of 
heparin  on  affinity may be  attributed  to stabilization  of 
NK1, dimerization of the ligand, or a bridging effect of the 
heparin chain between NK1 and the cell surface. It should 
be  noted  that  the  affinity  of NK1  for  BaF3-hMet  cells 
measured here is lower than that reported for c-Met (16). 
The reason for this difference is unclear, but it may be due 
to differences in the methods used to measure binding. 
That the heparin dose-response curve for NK1 activity 
was bell-shaped is consistent with a  dimerization mecha- 
nism;  as  the  concentration  of  the  dimerizing  agent  in- 
creases, the ratio of it to the dimerized factor goes from 1:2 
to  1:1. Direct  evidence  for  a  role  of dimerization  came 
from cross-linking studies that revealed that heparin induced 
NK1 to form dimers, along with smaller amounts of higher 
order  multimers.  Dextran  sulfate,  which  activates  NK1 
bioactivity,  also  induced  dimerization,  whereas  similarly 
sized but unsulfated dextran, which has no effect on NK1 
bioactivity, did not. Moreover, we found that the heparin 
dose-response  curve  for  dimerization,  like  the  heparin 
dose-response curve for NK1 activity, was bell-shaped. A 
very faint band in the dimer position was sometimes ob- 
served in samples of NK1 without heparin, suggesting that 
NK1 may have a tendency to form weakly associated dimers 
spontaneously.  Heparin  and  related  glycosaminoglycans 
may stabilize  the  dimer,  shifting the  equilibrium  toward 
the dimer. Taken together, the cross-linking data suggest 
that dimerization is important in the heparin mechanism. 
Based on our findings with exogenous heparin, we pro- 
pose that the agonist activity of NK1 in mink lung cells is 
due to an activating interaction of NK1 with endogenous 
heparin-like glycosaminoglycans on the cell surface. Con- 
sistent with that hypothesis, we found that mink lung cells 
had a high capacity to bind NK1 and that most of the NK1 
binding could be inhibited by heparin. The inhibitory ef- 
fect of heparin on NK1 binding was not a general phenom- 
enon  because  it  had  the  opposite  effect,  i.e.,  increased 
NK1  binding,  in  BaF3-hMet  cells,  which  do  not  express 
cell surface HSPGs. Thus, in mink lung cells NK1 interacts 
with a heparin-like molecule on the surface. The nature of 
this hypothetical cofactor is unknown, but we found that a 
variety of sulfated polysaccharides could substitute for hep- 
arin. Sulfation was critical for activity, but the sulfate moi- 
ety had to be present in  the  context of a  polysaccharide 
backbone. Heparan sulfate had no effect on NK1 activity 
but enhanced the response to NK2 and full-length HGF, 
suggesting  that  heparan  sulfate  may  interact  selectively 
with  kringle  2,  which  has  been  identified  as  a  heparin- 
binding region in full-length HGF (19). The negative data 
with  heparan  sulfate  and  NK1  also  suggests  that  if our 
model is correct, then  glycosaminoglycans on mink lung 
cells must  resemble heparin more  than  heparan  sulfate. 
Alternatively, commercial preparations of heparan sulfate 
may differ in charge and charge-density from heparan sul- 
fate on the surface of a living mink lung cell. 
We made several attempts to determine whether the re- 
sponse of mink lung cells to NK1 could be abrogated by di- 
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heparatinase. Although such treatment removed ~80% of 
the  heparin-displaceable  NK1  binding,  the  cells  still  re- 
sponded to NK1 (data not shown). Adding chlorate to the 
medium  also  failed  to  block  NK1  responses  (data  not 
shown). There are several potential explanations for these 
observations. First, the proposed NK1 cofactor could be 
insensitive to heparatinase and turn over too slowly for its 
sulfation to be affected by chlorate in the time frame of 
our experiments. Consistent with that concept, heparinase 
treatment completely eliminated heparin-displaceable HGF 
binding (data not shown), but a residual amount of hep- 
arin-displaceable NK1 binding always remained. Moreover, 
as noted above, our finding that heparan sulfate could not 
substitute for heparin suggests that the proposed NK1 co- 
factor is  more  similar  to  heparin  than  heparan  sulfate. 
That would also be consistent with our heparatinase data 
because heparatinase cleaves heparan sulfate-like glycosami- 
noglycans but not heparin-like glycosaminoglycans. Alter- 
natively, the endogenous cofactor that we have hypothe- 
sized  could  be  chondroitin  sulfate  or  another  sulfated 
glycosaminoglycan.  In  addition,  it  could  be  a  sulfogly- 
colipid  such  as  galactosylceramide 3'-sulfate,  which  has 
been shown to bind HGF with high affinity (14). Interest- 
ingly, the binding of HGF to this sulfated lipid is competed 
by heparin (14). 
Although we have been unable to nullify NK1 activity 
by enzymatically removing endogenous glycosaminogly- 
cans,  a  crude preparation  of cell  surface  proteoglycans 
from mink lung cells induced dimerization of NK1. The 
principle responsible for the dimerization activity in this 
preparation is undefined, but it is resistant to trypsin and 
boiling and has sufficient negative charge at neutral pH to 
bind tightly to an anion exchange resin. These characteris- 
tics  are  consistent with  a  glycosoaminoglycan. That  the 
dimerizing activity was released by trypsin suggests that it 
was  derived from a  proteoglycan, providing strong  evi- 
dence to support our model. The nature of the active com- 
ponent in this preparation is currently under evaluation. 
The stabilizing effect of heparin on NK1 may be impor- 
tant  in  interpreting  some  of the  data  from BaF3-hMet 
cells. As noted above, a small [3H]thymidine response in 
BaF3-hMet cells was observed with high doses of NK1 in 
the absence of heparin. Combined with the decay of bioac- 
tive NK1 in BaF3 medium without heparin, this result sug- 
gests that the normal response to NK1 in BaF3-hMet cells 
may be agonistic, but that the response is weak because 
NK1 is unstable. This would also explain why NK1 in the 
absence of heparin was a poor HGF antagonist in these 
cells. If our model is correct, then BaF3 cells may have low 
amounts of an endogenous factor that can activate NK1. 
Although BaF3 cells do not express the proteoglycan core 
protein syndecan  (25),  there  is  a  report that  32D  cells, 
which resemble BaF3 in many ways, incorporate 32SO4  into 
a 150-kD protein that is resistant to heparinase but sensitive 
to chondroitinase (27), and we have found that chondroitin 
sulfate  activates NK1  (see Table III).  Other  candidates 
that could subserve this function include glycosaminogly- 
cans tethered to the cell membrane through phosphoinosi- 
tol  linkages  (12),  and  the  above  noted  sulfoglycolipids, 
which have been reported to bind tightly to HGF (14). 
Although the synergism between heparin and NK1  in 
BaF3-hMet cells may be due, at least partly, to stabiliza- 
tion of NK1, other mechanisms must also be involved. In 
hepatocytes, NK1 is an antagonist in the absence of hep- 
arin, indicating that it is stable under those conditions but 
behaves as an antagonist rather than an agonist. One pos- 
sibility is that hepatocytes have an endogenous inhibitor 
that prevents NK1  from activating c-Met. However, the 
fact that heparin converts NK1 to an agonist in hepato- 
cytes, and  does  so  at  heparin  concentrations similar  to 
those that work in BaF3-hMet cells, argues against an in- 
hibitor. Our cross-linking studies strongly argue that the 
other mechanism is heparin-induced dimerization, which 
in turn can facilitate dimerization and activation of c-Met. 
We propose that the endogenous glycosaminoglycans on 
hepatocytes are incompetent in this regard, but responses 
can be elicited if exogenous heparin is supplied. By anal- 
ogy, the glycosaminoglycans of B5/589 cells, in which NK2 
is an antagonist (3), must also be incompetent. How such 
competence is conferred is unclear, but our results suggest 
that the degree of sulfation may be one mechanism. 
We  have  shown  that  heparin  and  heparin-like  gly- 
cosaminoglycans can also confer proliferative activity on 
the naturally occurring variant NK2, which, like NK1, was 
originally described as a competitive HGF antagonist (3). 
Since NK2 is very similar to NK1, most of the mechanistic 
discussion  above  should  be  equally  applicable  to  NK2, 
with the exception that heparan sulfate was able to pro- 
mote the activity of NK2 but not NK1. The latter observa- 
tion suggests that heparan sulfate may interact with krin- 
gle  2,  which  has  been  identified  as  a  heparin-binding 
domain in full-length HGF (19). Because NK2 mRNA is 
expressed in normal tissues such as the placenta (18), it is 
likely to have a physiological function in regulating HGF 
sensitivity. Our data suggest that glycosaminoglycans can 
be  important  in  determining  whether  NK2  antagonizes 
HGF activity, providing a novel mechanism by which net 
HGF activity might be fine tuned. 
Our findings might also help to explain why NK2 retains 
the scattering but not the mitogenic activity of full-length 
HGF (10). Those authors concluded that binding to c-Met 
by NK2 selectively triggers the intracellular signals involved 
in the motility response, but that full-length HGF is re- 
quired to trigger intracellular signaling cascade involved in 
mitogenesis. However, scattering was analyzed in MDCK 
cells, while mitogenesis was tested in hepatocytes. The ag- 
onist activity of NK2 on MDCK cells could be analogous 
to the agonist activity of NK1  and NK2 we observed in 
mink lung cells; i.e., NK1 and NK2 may be mimicking a 
normal  HGF  response  in  each  cell  type:  scattering  in 
MDCK cells and DNA synthesis in mink lung cells. Thus, 
the  selective  scattering  activity of NK2  may be  related 
more to differences in the proteoglycans on the surface of 
the cells used to test scattering and mitogenesis than on 
the  ability of NK2 to preferentially activate a  scattering 
domain of c-Met. 
In conclusion, we report here that heparin and heparin- 
like glycosaminoglycans synergize with NK1 and the natu- 
rally occurring variant NK2 to promote proliferative activ- 
ity in cells expressing the HGF receptor, c-Met. Clearly, 
NK1 +  heparin is not equivalent to full-length HGF, and 
regions of HGF from kringle 1 to the COOH terminus are 
very important in HGF's potency and biological activity. 
Schwall et al. Heparin Promotes Agonist Activity of  NKI and NK2  717 But the ability of heparin and related glycosaminoglycans 
to confer any agonistic activity onto NK1 and NK2 has im- 
plications for the use of these variants to pharmacologi- 
cally antagonize HGF. In addition, our results suggest that 
changes in glycosaminoglycan structure on the surface of a 
target cell, either through changes in proteoglycan expres- 
sion or through alterations inflicted by enzymes in the mi- 
lieu, may provide a novel mechanism by which responsive- 
ness  to  endogenous NK2,  and  thereby  to HGF,  can be 
locally regulated  in different  physiological and develop- 
mental states. 
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